APPLICATION OF PHOSPHODIESTERASE TYPE 5 INHIBITORS SILDENAFIL IN PATIENTS WITH PULMONARY HYPERTENSION

APPLICATION OF PHOSPHODIESTERASE TYPE 5 INHIBITORS SILDENAFIL IN PATIENTS WITH PULMONARY HYPERTENSION

The key component of the pathogenesis of pulmonary hypertension (PH) is endothelial dysfunction with imbalance between vasodilators and vasoconstrictors and activation of the blood coagulation system. Randomized trials showed a beneficial effect of phosphodiesterase type 5 (PDE-5) inhibitors on vasc...

Full description

Bibliographic Details
Main Authors: T. V. Martynyuk, Z. H. Dadacheva, V. M. Paramonov, O. A. Arkhipova, S. N. Nakonechnikov, I. Ye. Chazova
Format: Article
Language:Russian
Published: InterMedservice 2015-06-01
Series:Евразийский Кардиологический Журнал
Subjects:
легочная гипертензия
легочная артериальная гипертензия
хроническая тромбоэмболическая лёгочная гипертензия
оксид азота
цгмф
ингибиторы фосфодиэстеразы типа 5
силденафил
pulmonary hypertension
pulmonary arterial hypertension
nitric oxide
cyclic guanosine-monophosphate
pde-5 inhibitors
sildenafil
Online Access:https://www.heartj.asia/jour/article/view/5633

Internet

https://www.heartj.asia/jour/article/view/5633

Similar Items